Karin L. Walker - Mar 20, 2023 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Role: Chief Accounting Officer
Signature: /s/ Michael Malecek, as Attorney in Fact for Karin L. Walker
Stock symbol: PRTA
Transactions as of: Mar 20, 2023
Transactions value $: -$163,410
Form type: 4
Date filed: 3/22/2023, 09:30 PM
Previous filing: Mar 17, 2023
Next filing: Apr 21, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Options Exercise	$75.2K	+5K		$15.04^*	5K	Mar 20, 2023	Direct
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Sale	-$185K	-3.9K	-78.06%	$47.51	1.1K	Mar 20, 2023	Direct	F1, F2
transaction	PRTA	Ordinary Shares, par value $0.01 per share	Sale	-$53.2K	-1.1K	-100%	$48.47	0	Mar 20, 2023	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRTA	Stock Option (right to buy)	Options Exercise	$0	-5K	-14.09%	$0.00	30.5K	Mar 20, 2023	Ordinary Shares	5K	$15.04	Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The transaction was executed in multiple trades in prices ranging from $47.305 to $48.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4.
F3	The transaction was executed in multiple trades in prices ranging from $48.33 to $48.73, inclusive.
F4	The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on June 21, 2019, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
F5	The Reporting Person's prior Form 4 filed on March 17, 2023 inadvertently transposed the first two digits of the number of options reported in Column 9, reporting 53,481 options beneficially owned following the Reporting Person's transaction in these options on March 15, 2023, instead of the correct number of 35,481 options beneficially owned. The correct number of 35,481 options beneficially owned was used for purposes of calculating the number of options reported in Column 9 of this Form 4.